EA201791733A1 - Производные 9h-пирролодипиридина - Google Patents

Производные 9h-пирролодипиридина

Info

Publication number
EA201791733A1
EA201791733A1 EA201791733A EA201791733A EA201791733A1 EA 201791733 A1 EA201791733 A1 EA 201791733A1 EA 201791733 A EA201791733 A EA 201791733A EA 201791733 A EA201791733 A EA 201791733A EA 201791733 A1 EA201791733 A1 EA 201791733A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pyrrolodipyridine
derivatives
radiopharmaceuticals
determination
formula
Prior art date
Application number
EA201791733A
Other languages
English (en)
Other versions
EA036518B1 (ru
Inventor
Жоэль Мерсье
Лоран Провен
Селин Вермерен
Йогеш Анил Сабнис
Original Assignee
Юсб Байофарма Спрл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юсб Байофарма Спрл filed Critical Юсб Байофарма Спрл
Publication of EA201791733A1 publication Critical patent/EA201791733A1/ru
Publication of EA036518B1 publication Critical patent/EA036518B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Abstract

Настоящее изобретение относится к производным 9H-пирролодипиридина формулы I, к способам их получения, содержащим их фармацевтическим композициям и к их применению в качестве радиофармацевтических средств, в частности в качестве визуализирующих средств для определения агрегатов тау-белка.
EA201791733A 2015-02-02 2016-01-29 Производные 9h-пирролодипиридина EA036518B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15153448 2015-02-02
PCT/EP2016/051993 WO2016124508A1 (en) 2015-02-02 2016-01-29 9h-pyrrolo-dipyridine derivatives

Publications (2)

Publication Number Publication Date
EA201791733A1 true EA201791733A1 (ru) 2018-01-31
EA036518B1 EA036518B1 (ru) 2020-11-18

Family

ID=52477553

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791733A EA036518B1 (ru) 2015-02-02 2016-01-29 Производные 9h-пирролодипиридина

Country Status (17)

Country Link
US (3) US20180022748A1 (ru)
EP (1) EP3253762B1 (ru)
JP (1) JP6579670B2 (ru)
KR (1) KR102621513B1 (ru)
CN (1) CN107207508B (ru)
AU (1) AU2016214537B2 (ru)
BR (1) BR112017016311A2 (ru)
CA (1) CA2973648C (ru)
CL (1) CL2017001923A1 (ru)
DK (1) DK3253762T3 (ru)
EA (1) EA036518B1 (ru)
ES (1) ES2875734T3 (ru)
IL (1) IL253381B (ru)
MX (1) MX2017009505A (ru)
MY (1) MY191590A (ru)
SG (1) SG11201705727TA (ru)
WO (1) WO2016124508A1 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009102498A1 (en) 2008-02-14 2009-08-20 Siemens Medical Solutions Usa, Inc. Novel imaging agents for detecting neurological dysfunction
MY191590A (en) * 2015-02-02 2022-06-30 Ucb Biopharma Sprl 9h-pyrrolo-dipyridine derivatives
JP7059270B2 (ja) * 2016-07-22 2022-04-25 エーシー・イミューン・エス・アー タウタンパク質凝集体を画像化するための化合物
CA3030511A1 (en) 2016-07-22 2018-01-25 Ac Immune S.A. Compounds for imaging tau protein aggregates
BR112019004091B1 (pt) * 2016-09-09 2023-02-14 F. Hoffmann-La Roche Ag Processo para a preparação de 2-(6-nitropiridin-3-il)-9h-dipirido[2,3-b;3', 4'-d]pirrol
CA3042260C (en) * 2016-11-01 2023-10-03 Arvinas, Inc. Tau-protein targeting protacs and associated methods of use
EP3632430A4 (en) 2017-06-02 2020-06-10 FUJIFILM Toyama Chemical Co., Ltd. AGENT FOR THE PREVENTION OR TREATMENT OF SPINOCEREBELLOUS ATAXIA
WO2018221731A1 (ja) * 2017-06-02 2018-12-06 富山化学工業株式会社 タウオパチー予防または治療剤
RU2759727C2 (ru) 2017-06-02 2021-11-17 ФУДЖИФИЛМ Тояма Кемикал Ко., Лтд. Средство для профилактики или лечения атрофии головного мозга
BR112019024983A2 (pt) 2017-06-02 2020-06-23 Fujifilm Toyama Chemical Co., Ltd. Agente para reduzir a quantidade de proteína b amiloide
US11541033B2 (en) 2017-06-02 2023-01-03 Fujifilm Toyama Chemical Co., Ltd. Agent for preventing or treating Alzheimer's disease
JP7227914B2 (ja) 2017-10-30 2023-02-22 富士フイルム富山化学株式会社 エモパミル結合タンパク質結合剤およびその利用
WO2019145291A1 (en) 2018-01-24 2019-08-01 Ac Immune Sa Gamma-carboline compounds for the detection of tau aggregates
EP3743426A1 (en) * 2018-01-24 2020-12-02 AC Immune SA Azacarboline compounds for the detection of tau aggregates
EA202091767A1 (ru) * 2018-01-24 2021-02-16 Ац Иммуне Са Новый способ получения визуализирующего соединения
WO2021011913A1 (en) 2019-07-17 2021-01-21 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1268771A (en) 1968-03-15 1972-03-29 Glaxo Lab Ltd Azacarbazoles
WO2008132454A1 (en) * 2007-04-26 2008-11-06 Ge Healthcare Limited Carbolines and their use as imaging agents
WO2009102498A1 (en) * 2008-02-14 2009-08-20 Siemens Medical Solutions Usa, Inc. Novel imaging agents for detecting neurological dysfunction
EP2370407B1 (en) * 2008-12-19 2014-06-18 Bristol-Myers Squibb Company Carbazole and carboline kinase inhibitors
WO2013176698A1 (en) * 2012-05-22 2013-11-28 Eli Lilly And Company Carboline and carbazole based imaging agents for detecting neurological dysfunction
US20160115162A1 (en) * 2013-05-31 2016-04-28 The General Hospital Corporation Radiosynthesis of Tau Radiopharmaceuticals
US9774356B2 (en) * 2013-07-24 2017-09-26 Telefonaktiebolaget Lm Ericsson (Publ) Method and apparatus relating to reception of radio signals
EP3055308B1 (en) * 2013-10-08 2017-11-22 F.Hoffmann-La Roche Ag Diazacarbazole derivatives as tau-pet-ligands
US10662193B2 (en) * 2014-01-21 2020-05-26 Ac Immune Sa Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins
MY191590A (en) * 2015-02-02 2022-06-30 Ucb Biopharma Sprl 9h-pyrrolo-dipyridine derivatives

Also Published As

Publication number Publication date
EP3253762B1 (en) 2021-05-05
BR112017016311A2 (pt) 2018-03-27
CN107207508B (zh) 2020-02-28
IL253381B (en) 2020-10-29
CA2973648A1 (en) 2016-08-11
US20210047326A1 (en) 2021-02-18
US20220213103A1 (en) 2022-07-07
KR20170113607A (ko) 2017-10-12
SG11201705727TA (en) 2017-08-30
DK3253762T3 (da) 2021-07-19
IL253381A0 (en) 2017-09-28
JP6579670B2 (ja) 2019-09-25
CN107207508A (zh) 2017-09-26
CA2973648C (en) 2023-09-26
EP3253762A1 (en) 2017-12-13
CL2017001923A1 (es) 2018-02-16
MY191590A (en) 2022-06-30
US11312716B2 (en) 2022-04-26
WO2016124508A1 (en) 2016-08-11
US20180022748A1 (en) 2018-01-25
AU2016214537B2 (en) 2018-05-10
ES2875734T3 (es) 2021-11-11
EA036518B1 (ru) 2020-11-18
KR102621513B1 (ko) 2024-01-04
JP2018503673A (ja) 2018-02-08
AU2016214537A1 (en) 2017-08-03
MX2017009505A (es) 2017-11-02

Similar Documents

Publication Publication Date Title
EA201791733A1 (ru) Производные 9h-пирролодипиридина
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
EA201792047A1 (ru) Новые соединения
EA201590931A1 (ru) Гетероциклические замещенные производные 2-амино-хиназолина для лечения вирусных инфекций
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591524A1 (ru) Производные 2-аминопиримидина для лечения вирусных инфекций
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201790248A1 (ru) Композиции носитель-антитело и способы их получения и применения
EA202090547A3 (ru) Макроциклические деаза-оксипурины для лечения вирусных инфекций
MX2016014615A (es) Compuestos heterociclicos deuterados y su uso como agentes formadores de imagenes.
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
EA201491644A1 (ru) Фармацевтические композиции
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
EA201591748A1 (ru) Модуляторы p2x7
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA201890331A1 (ru) Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
EA201690159A1 (ru) Способы и композиции для лечения рака
EA202191513A1 (ru) Снижение вязкости фармацевтических составов
EA201790570A1 (ru) Модуляторы р2х7
EA201790949A1 (ru) Замещенные 2,4-диаминохинолины в качестве новых противораковых средств
EA201591451A1 (ru) Модуляторы flap
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM